Therapeutic aspects of growth hormone and insulin-like growth factor-I treatment on visceral fat and insulin sensitivity in adults (Q36697737)

15 August 2017

1 reference

title

Therapeutic aspects of growth hormone and insulin-like growth factor-I treatment on visceral fat and insulin sensitivity in adults (English)

1 reference

15 August 2017

1 reference

Yuen KC

1

1 reference

15 August 2017

Dunger DB

series ordinal

2

1 reference

15 August 2017

publication date

1 January 2007

1 reference

Diabetes, Obesity and Metabolism

15 August 2017

published in

1 reference

15 August 2017

volume

9

1 reference

15 August 2017

issue

1

1 reference

15 August 2017

page(s)

11-22

1 reference

The effect of 30 months of low-dose replacement therapy with recombinant human growth hormone (rhGH) on insulin and C-peptide kinetics, insulin secretion, insulin sensitivity, glucose effectiveness, and body composition in GH-deficient adults.

15 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2006.00591.X

Growth hormone replacement therapy induces insulin resistance by activating the glucose-fatty acid cycle

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2006.00591.X

Effects of growth hormone (GH) on ghrelin, leptin, and adiponectin in GH-deficient patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2006.00591.X

Effects of 10 years of growth hormone (GH) replacement therapy in adult GH-deficient men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2006.00591.X

One year of GH replacement therapy with a fixed low-dose regimen improves body composition, bone mineral density and lipid profile of GH-deficient adults.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2006.00591.X

Glucose metabolism and visceral fat in GH deficient adults: 1 year of GH replacement

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2006.00591.X

Glucose metabolism and visceral fat in GH deficient adults: two years of GH-replacement

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2006.00591.X

Insulin-like growth factors and their binding proteins: biological actions

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2006.00591.X

The somatomedin hypothesis: 2001.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2006.00591.X

The glucose fatty-acid cycle. Its role in insulin sensitivity and the metabolic disturbances of diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2006.00591.X

Metasomatotrophic diabetes and its induction: basal insulin secretion and insulin release responses to glucose, glucagon, arginine and meals.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2006.00591.X

Binding proteins for the insulin-like growth factors: structure, regulation and function

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2006.00591.X

Development and clinical evaluation of a novel immunoassay for the binary complex of IGF-I and IGF-binding protein-1 in human serum.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2006.00591.X

Regulation of the growth hormone (GH) receptor and GH-binding protein mRNA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2006.00591.X

Changes in free rather than total insulin-like growth factor-I enhance insulin sensitivity and suppress endogenous peak growth hormone (GH) release following short-term low-dose GH administration in young healthy adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2006.00591.X

Inhibition of lipolysis during acute GH exposure increases insulin sensitivity in previously untreated GH-deficient adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2006.00591.X

Commencing growth hormone replacement in adults with a fixed low dose. Effects on serum lipoproteins, glucose metabolism, body composition, and cardiovascular function.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2006.00591.X

Long-term monitoring of insulin sensitivity in growth hormone-deficient adults on substitutive recombinant human growth hormone therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2006.00591.X

The effects of GH replacement in adult GH-deficient patients: changes in body composition without concomitant changes in the adipokines and insulin resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2006.00591.X

Survivors of childhood acute lymphoblastic leukaemia, with radiation-induced GH deficiency, exhibit hyperleptinaemia and impaired insulin sensitivity, unaffected by 12 months of GH treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2006.00591.X

Can growth hormone therapy cause diabetes? KIMS Strategic Committee.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2006.00591.X

Insulin-like growth factors I and II.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2006.00591.X

Increases in free, unbound insulin-like growth factor I enhance insulin responsiveness in human hepatoma G2 cells in culture

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2006.00591.X

Functional inactivation of the IGF-I and insulin receptors in skeletal muscle causes type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2006.00591.X

Insulin-like growth factor (IGF)-I gene deletion

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2006.00591.X

Insulin-like growth factor I has a direct effect on glucose and protein metabolism, but no effect on lipid metabolism in type 1 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2006.00591.X

The combination of insulin-like growth factor I and insulin-like growth factor-binding protein-3 reduces insulin requirements in insulin-dependent type 1 diabetes: evidence for in vivo biological activity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2006.00591.X

Rh/IGF-I/rhIGFBP-3 administration to patients with type 2 diabetes mellitus reduces insulin requirements while also lowering fasting glucose

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2006.00591.X

Growth hormone replacement therapy for adults: into the new millennium.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2006.00591.X

Association between premature mortality and hypopituitarism. West Midlands Prospective Hypopituitary Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2006.00591.X

Effects of seven years of GH-replacement therapy on insulin sensitivity in GH-deficient adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2006.00591.X

Improvement in insulin sensitivity without concomitant changes in body composition and cardiovascular risk markers following fixed administration of a very low growth hormone (GH) dose in adults with severe GH deficiency

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2006.00591.X

Growth hormone-deficient adults are insulin-resistant.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2006.00591.X

Low-dose recombinant human growth hormone as adjuvant therapy to lifestyle modifications in the management of obesity

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2006.00591.X

Growth hormone treatment reduces abdominal visceral fat in postmenopausal women with abdominal obesity: a 12-month placebo-controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2006.00591.X

Short-term low-dose growth hormone administration in subjects with impaired glucose tolerance and the metabolic syndrome: effects on beta-cell function and post-load glucose tolerance

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2006.00591.X

Effects of growth hormone replacement therapy on metabolic and cardiac parameters, in adult patients with childhood-onset growth hormone deficiency

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2006.00591.X

Absence of effects of long-term growth hormone replacement therapy on insulin sensitivity in adults with growth hormone deficiency of childhood-onset (GHDA-CO).

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2006.00591.X

Growth Hormone (GH) Dose-Response in Young Adults with Childhood-Onset GH Deficiency: A Two-Year, Multicenter, Multiple-Dose, Placebo-Controlled Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2006.00591.X

Randomised placebo-controlled trial of human recombinant insulin-like growth factor I plus intensive insulin therapy in adolescents with insulin-dependent diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2006.00591.X

Recombinant human insulin-like growth factor-I (rhIGF-I) therapy in adults with type 1 diabetes mellitus: effects on IGFs, IGF-binding proteins, glucose levels and insulin treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2006.00591.X

Short-term effects of recombinant human insulin-like growth factor I on metabolic control of patients with type II diabetes mellitus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2006.00591.X

Changes in insulin-like growth factor (IGF)-binding proteins after IGF-I injections in noninsulin-dependent diabetics.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2006.00591.X

Insulin-like growth factor I (rhIGF-I) as a therapeutic agent for hyperinsulinemic insulin-resistant diabetes mellitus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2006.00591.X

Contrasting metabolic effects of continuous and pulsatile growth hormone administration in young adults with Type 1 (insulin-dependent) diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2006.00591.X

The relationship between overnight GH levels and insulin concentrations in adolescents with insulin-dependent diabetes mellitus (IDDM) and the impact of recombinant human insulin-like growth factor I (rhIGF-I)

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2006.00591.X

Effects of low-dose recombinant human insulin-like growth factor-I on insulin sensitivity, growth hormone and glucagon levels in young adults with insulin-dependent diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2006.00591.X

Recombinant human insulin-like growth factor-I abolishes changes in insulin requirements consequent upon growth hormone pulsatility in young adults with type I diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2006.00591.X

10.1111/J.1463-1326.2006.00591.X

21 January 2018

Identifiers

DOI

1 reference

15 August 2017

1 reference